March 25, 2008--APP Pharmaceuticals, Inc. (Nasdaq:APPX), a leading manufacturer of multi-source and branded injectable pharmaceutical products, today announced that it has launched Cefepime Hydrochloride for Injection, the generic equivalent of Maxipime(R) marketed by Elan Corporation, plc. APP's cefepime is AP-rated, bar-coded and latex-free. According to IMS data, sales of Cefepime Hydrochloride in the United States were approximately $173 million in 2007.
Cefepime Hydrochloride for Injection is indicated in the treatment of the following infections: Pneumonia, Empiric Therapy for Febrile Neutropenic Patients, Urinary Tract Infections (including pyelonephritis), Skin and Skin Structure Infections, and Intra-abdominal Infections.
"The launch of Cefepime further bolsters our leadership position as a provider of the broadest portfolio of generic anti-infective injectable products," said Tom Silberg, President of APP. "APP is one of the only marketers of first, second, third and fourth generation cephalosporin in the U.S."
No comments:
Post a Comment